Clinical Trials Logo

Clinical Trial Summary

Patients with hepatocellular carcinoma often die from intrahepatic disease because current treatment options are limited. Local treatment using 166Ho-radioembolization (166Ho-RE) offers a safe and effective treatment. Because 166Ho-microspheres are used as a scout dose for treatment simulaton and for the actual treatment itself, a tailored approach can be used. This concept has proven to be more predictive than the 90Y-radioembolization concept (current standard-of-care), which is a based on a surrogate scout dose (i.e. 99mTc-MAA). A personal treatment plan may be used for 166Ho-radioembolization to optimize efficacy, based on scout dose distribution. However, individualized treatment planning inherently leads to treatment doses that deviate from the currently approved 'one-size-fits-all' approach (i.e. 60 Gy average absorbed dose for all patients). Therefore, safety of individualized 166Ho-RE will be evaluated first to validate safety and confirm safety thresholds. These thresholds will be used in subsequent randomized controlled studies.

Clinical Trial Description

The presented study proposal is a sequel study after a successful completion of the HEPAR Primary study (all patients were treated, last follow-up visit planned for August 2020). In the HEPAR Primary study, all treatments were planned using one compartment modeling, which included the target volume without distinction between tumor and non-tumor compartments. Each patient was treated with an average absorbed dose of 60 Gy in the target volume. In some patients this treatment approach resulted in a high tumor and low normal liver absorbed dose, in others this resulted in the opposite. No distinction was made because thresholds for a safe normal liver and effective tumor absorbed dose were not known, since HEPAR Primary was the first clinical study on 166Ho-RE in HCC. The study confirmed safety of a 60 Gy average absorbed dose and gave insights in the previously unknown thresholds for a safe normal liver and effective tumor absorbed dose. The primary hypothesis of the iHEPAR study is that dosimetry-based individualized treatment planning is at least as safe as standard of care one compartment treatment planning, used in HEPAR Primary, but with the potential of improved treatment outcomes. One compartment modeling has the inherent risk of under- or over-dosing. Dosimetry-based individualized treatment planning aims for an effective tumor absorbed dose, while keeping the non-tumor absorbed dose within safety limits. So far, only one compartment modeling was established as a safe and effective treatment approach in 166Ho-RE. This phase II study aims to evaluate the safety and efficacy of dosimetry-based individualized 166Ho-RE in HCC. This data will be used for the design of future randomized controlled trials. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05114148
Study type Interventional
Source UMC Utrecht
Status Not yet recruiting
Phase N/A
Start date November 1, 2021
Completion date November 1, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05031949 - Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma Phase 1
Active, not recruiting NCT04592029 - TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC Phase 1
Not yet recruiting NCT03283956 - Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan N/A
Recruiting NCT03652467 - The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma Phase 1
Completed NCT03533920 - Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma N/A
Not yet recruiting NCT05057104 - Non-inferiority Study of Unresectable Hepatocelluar Carcinoma Receiving Stereotactic Radiotherapy Combined With Hepatic Arterial Chemoembolization Compared With Conversion Hepatectomy
Recruiting NCT04599777 - TACE Combined With Sorafenib and Tislelizumab for Advanced HCC Phase 2
Recruiting NCT04599790 - TACE Combined With Lenvatinib and Sintilimab for Advanced HCC Phase 2
Recruiting NCT02967887 - Evaluation of Hepatic Arterial Infusion of Cisplatin and 5-FU in Biomarker Stratified HCC Phase 2
Active, not recruiting NCT02989922 - A Study to Evaluate SHR-1210 in Subjects With Advanced HCC Phase 2
Recruiting NCT04273100 - PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC Phase 2
Withdrawn NCT03563170 - QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine Phase 1/Phase 2
Enrolling by invitation NCT04997850 - The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma Phase 1/Phase 2
Completed NCT03138031 - Percutaneous Ethanol Alcohol Injection for the Large and Unresectable Hepatocellular Carcinoma N/A
Recruiting NCT03881501 - Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma
Recruiting NCT03864211 - Thermal Ablation Followed by Immunotherapy for HCC Phase 1/Phase 2
Recruiting NCT04967482 - DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC N/A
Recruiting NCT04967495 - TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT N/A
Recruiting NCT04718909 - Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC Phase 2
Not yet recruiting NCT03807947 - Radial Versus Femoral Access for Superselective Embolization of Hepatocellular Carcinoma N/A